Diaceutics PLC Change of Auditor (8460H)
29 November 2022 - 6:00PM
UK Regulatory
TIDMDXRX
RNS Number : 8460H
Diaceutics PLC
29 November 2022
29 November 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Change of Auditor
Diaceutics PLC , ( AIM: DXRX), a leading diagnostic
commercialisation company which provides data, analytics and
technology enabled services via its proprietary DXRX platform to
the Precision Medicine market announces that, following the
conclusion of a formal tender process led by the Company's Audit
Committee, the Board has approved the proposed appointment of Ernst
& Young ("EY") as the Company's auditor for the financial year
ending 31 December 2022. A proposal to re-appoint EY will be
subject to approval by the Company's shareholders at the next
Annual General Meeting to be held in 2023.
PricewaterhouseCoopers LLP, the Company's current auditor, has
resigned and has confirmed that there are no matters connected with
it ceasing to hold office that should be brought to the attention
of the members or creditors of the Company.
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Diaceutics' data capability is one of the three key value
drivers it has integrated into its unique DXRX platform alongside
its global Lab network and product suite tailored for Precision
testing.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPBKFBKCBDDQDB
(END) Dow Jones Newswires
November 29, 2022 02:00 ET (07:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024